Basic Science and Pathogenesis.

Background: Despite amyloid-β (Aβ) plaques and tau neurofibrillary tangles being recognized as major Alzheimer's Disease (AD) hallmarks, their synergistic contribution to neuronal activity remains unclear. We developed a neuroimaging-based personalized brain activity model to assess the in-vivo functional impact of AD pathophysiology. In previous reports, model-inferred neuronal excitability predicted disease progression (i.

Basic Science and Pathogenesis.

Background: Vascular cognitive impairment/dementia (VD) is the second most prevalent cause of dementia following Alzheimer's disease (AD). VD is characterized by the progression of white matter hyperintensity burden (WMH) and associated neurodegeneration. GFAP, a biomarker for reactive astrogliosis, is associated with Aβ pathology and mediates tau-pathology in preclinical AD.

Basic Science and Pathogenesis.

Background: Intracellular accumulation of tau tangles in the brain is one of the most prominent manifestations of Alzheimer's disease (AD). Progression thereof across the AD stages has specific temporal and spatial patterns, wherein time is informative of space and vice versa. Here we introduce a novel method, Manifold Component Analysis (MCA), to represent tangle accumulation in 2D, reflecting the spatial aspect of tau propagation stages to further relate it to the temporal aspect thereof.

A Rare Case of Scrotal Swelling: Prostate Cancer Metastasis Masquerading as a Complicated Hydrocele.

Metastasis of prostate cancer to the testes is exceptionally rare. We report the case of a 67-year-old male with a 10-year history of high-risk prostate cancer, previously treated and currently in remission, who presented with left scrotal swelling. The swelling was clinically and radiologically diagnosed as a hydrocele and treated surgically.

Implementation of Integrated Clinical Pharmacogenomics Testing at an Academic Medical Center.

Background: Pharmacogenomics has demonstrated benefits for clinical care, including a reduction in adverse events and cost savings. However, barriers in expanded implementation of pharmacogenomics testing include prolonged turnaround times and integration of results into the electronic health record with clinical decision support. A clinical workflow was developed and implemented to facilitate in-house result generation and incorporation into the electronic health record at a large academic medical center.